Article Per Year (5 Year)
p-Index From 2019 - 2024
0.23
P-Index
This Author published in this journals
All Journal JURNAL ILMU KEFARMASIAN INDONESIA
Astrid Kartika Sari
Unknown Affiliation
Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Analisis Dampak Program Pengelolaan Penyakit Kronis (Prolanis) Dalam Meningkatkan Outcome Klinis Pasien Diabetes Melitus Tipe 2 Di Puskesmas Jakarta, Indonesia Reise Manninda; Yusi Anggriani; Astrid Kartika Sari
JURNAL ILMU KEFARMASIAN INDONESIA Vol 19 No 2 (2021): JIFI
Publisher : Fakultas Farmasi Universitas Pancasila

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35814/jifi.v19i2.1107

Abstract

Prolanis is a Chronic Disease Management Program under the Indonesian National Health Insurance for promoting and preventing chronic disease. Main activities of Prolanis program are disease control and counseling, scheduled education, scheduled exercise, participant’s remainder, and home visit. The aim of this study was to evaluate the impact of prolanis on the clinical outcome in type 2 Diabetes Mellitus (DM) patients. An observational retrospective study was evaluated for 12 months. Data was collected from medical record. 426 patients from five primary health care center in Jakarta was selected by simple random sampling and divided into prolanis and non-prolanis groups. The indicators were the difference of clinical outcome between prolanis and non-prolanis patients was analyzed using Mann-Whitney test; the correlation of adherence with clinical outcome was analyzed using Chi-Square test.The results showed that prolanis patients had a significant improvement in Fasting Blood Glucose (FBG) compared with non-prolanis patients (P<0.05). The adherence of prolanis patients showed a significant improvement on FBG (124 patients-58.2%). Patients with nonadherence had lower improvement on FBG, the improvement was observed only at 16 patients (7.5%) and 60 patients (28.17%) was poor FBG. Prolanis is an effective program to improve the clinical outcome of DM patients.
Co-Authors Manninda, Reise Yusi Anggriani